|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastroenteropancreatic neuroendocrine tumours显示文摘 | Irvin M Modlin Kjell Oberg Daniel C Chung Robert T Jensen Wouter W de Herder Rajesh V Thakker Martyn Caplin Gianfranco Delle Fave Greg A Kaltsas Eric P Krenning Steven F Moss Ola Nilsson Guido Rindi Ramon Salazar Philippe Ruszniewski Anders Sundin | 2008 | Lancet Oncology2008，，1： | 8 |
| 2 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 3 | Primary phacoemulsification for uncontrolled angle-closure glaucoma 1 1 None of the authors has a financial or proprietary interest in any material or method mentioned.显示文摘 | Timothy V Roberts Ian C Francis Sam Lertusumitkul Medduma B Kappagoda Minas T Coroneo | 2000 | Journal of Cataract & Refractive Surgery2000，，7： | 3 |
| 4 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 5 | Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma显示文摘BACKGROUND Para-aortic lymph nodes(PALN)are found in the aortocaval groove and they are staged as metastatic disease if involved by pancreatic ductal adenocarcinoma(PDAC).The data in the literature is conflicting with some studies having associated PALN involvement with poor prognosis,while others not sharing the same results.PALN resection is not included in the standard lymphadenectomy during pancreatic resections as per the International Study Group for Pancreatic Surgery and there is no consensus on the management of these cases.AIM To investigate the prognostic significance of PALN metastases on the oncological outcomes after resection for PDAC.METHODS This is a retrospective cohort study of data retrieved from a prospectively maintained database on consecutive patients undergoing pancreatectomies for PDAC where PALN was sampled between 2011 and 2020.Statistical comparison of the data between PALN+and PALN-subgroups,survival analysis with the Kaplan-Meier method and risk analysis with univariable and multivariable time to event Cox regression analysis were performed,specifically assessing oncological outcomes such as median overall survival(OS)and disease-free survival(DFS).RESULTS 81 cases had PALN sampling and 17(21%)were positive.Pathological N stage was significantly different between PALN+and PALN-patients(P=0.005),while no difference was observed in any of the other characteristics.Preoperative imaging diagnosed PALN positivity in one case.OS and DFS were comparable between PALN+and PALN-patients with lymph node positive disease(OS:13.2 mo vs 18.8 mo,P=0.161;DFS:13 mo vs 16.4 mo,P=0.179).No difference in OS or DFS was identified between PALN positive and negative patients when they received chemotherapy either in the neoadjuvant or in the adjuvant setting(OS:23.4 mo vs 20.6 mo,P=0.192;DFS:23.9 mo vs 20.5 mo,P=0.718).On the contrary,when patients did not receive chemotherapy,PALN disease had substantially shorter OS(5.5 mo vs 14.2 mo;P=0.015)and DFS(4.4 mo vs 9.8 mo;P<0.001).PALN involvement was not identified as an independent predictor for OS after multivariable analysis,while it was for DFS doubling the risk of recurrence.CONCLUSION PALN involvement does not affect OS when patients complete the indicated treatment pathway for PDAC,surgery and chemotherapy,and should not be considered as a contraindication to resection. | Rupaly Pande Shafiq Chughtai Manish Ahuja Rachel Brown David C Bartlett Bobby V Dasari Ravi Marudanayagam Darius Mirza Keith Roberts John Isaac Robert P Sutcliffe Nikolaos A Chatzizacharias | 2022 | World Journal of Gastrointestinal Surgery2022，14，5： | 2 |
| 6 | Hyper-X Post-Flight Trajectory Reconstruction显示文摘 | Christopher D K Paul V T Robert C B | 2006 | Journal of Spacecraft and Rockets2006，43，1： | 1 |
| 7 | Determination of morphine and related alkaloids in crude morphine , poppy straw and opium preparations by micellar electrokinetic capil-lary chromatography显示文摘 | TRENERRY C V ROBERT J W JAMES R | 1995 | Journal of Chromatography A1995，，718： | 1 |
| 8 | Enforced expression of EBF in hematopoietic stem cells restricts lymphopoiesis to the B cell lineage显示文摘 | Zheng Z Claudiu V C Robert P Stephan | 2003 | EMBO J2003，22，： | 1 |
| 9 | A second conserved GAF domain cysteine is required for the blue/green photoreversibility of cy- anobacteriochrome TIr0924 from Thermosynecho- coccus elongates 显示文摘 | Rockwell N C Njuguna S L Roberts L Castillo E Parson V L Dwojak S Lagarias J C Spiller S C | 2008 | Biochemistry2008，47，： | 1 |
| 10 | Ectopic pregnancy in lower segment uterine scar显示文摘 | Roberts H Konhlenber C Lanzgrone V | | Aust N Z J Obst et Gynecol0，38，： | 1 |
| 11 | Nivolumab in Previously Un- treated Melanoma without BRAF Mutation显示文摘 | Robert C Long G V Brady B | 2015 | N Engl J Med2015，372，4： | 1 |
| 12 | Nivolumab in previously untreated melanoma without BRAF mutation 显示文摘 | Robert C Long G V Brady B | 2015 | N Engl J Med2015，372，4： | 1 |
| 13 | Techniques for the study and development of microbial fuel cells: an electrochemical perspective 显示文摘 | Zhao F Robert C T S John R V | 2009 | Chem Soc Rev2009，38，： | 1 |
| 14 | Ectopic pregnancy in lower segment uterine scar显示文摘 | Roberts H Kohlenber C Lanzarene V | 1998 | Aust N Z J Obstet Gynecol1998，38，1： | 1 |
| 15 | The induction in vitro of adventitious shoots in Rosa显示文摘 | LLOYD D ROBERTS A V SHORT K C | 1988 | Euphytica1988，37，： | 1 |
| 16 | Atom transfer radical polymerization of methyl acrylate from a multifunctional initiator at ambient temperature显示文摘 | ANNA C ROBERT V EVA M J | 2002 | Polymer2002，43，： | 1 |
| 17 | Myocardial production of aldosterone and corticasterone in the rat 显示文摘 | Silverstre JS Robert V Heymes C | 1998 | J Biol Chem1998，273，9： | 1 |
| 18 | A chimaeric ribonuclease-inhibitor gene restores fertility to male sterile plants显示文摘 | Mariani C Gosele V De Bluckeleer M De Block M Robert B Goldberg De Greef W Leemans J | 1992 | Nature1992，357，6： | 1 |
| 19 | Operative treatment of scapular fractures:a systematic review显示文摘 | Lantry J M Roberts C S Giannoudis P V | | 0，，03： | 1 |
| 20 | Cyclosporine A eyedrops:manufacturing toxicity, pharmacokinetics in 2000显示文摘 | Robert PY Leconte V Olive C | 2001 | J Fr Ophthalmol2001，24，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员